— Know what they know.
Not Investment Advice

AERI NASDAQ

Aerie Pharmaceuticals, Inc.
1W: +0.1% 1M: +0.3% 3M: +36.8% 1Y: +48.5% 3Y: -19.2% 5Y: -74.5%
$15.25
Last traded 2022-11-18 — delisted
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic

Balance Sheet Trends

Total Assets
$431M +7.3% ▲
5Y CAGR: +11.7%
Total Liabilities
$449M +18.7% ▲
5Y CAGR: +25.7%
Shareholders Equity
-$17M -172.3% ▼
Cash & Investments
$140M -41.8% ▼
5Y CAGR: -9.8%
Total Debt
$261M +21.1% ▲
5Y CAGR: +16.1%
Net Debt
$223M +250.7% ▲

Assets vs Liabilities & Equity

Year-over-Year Growth

View Full Balance Sheet
Line ItemFY2017FY2018FY2019FY2020FY2021
— Assets —
Cash$198M$203M$144M$152M$37M
Short-Term Investments$52M$0$165M$89M$103M
Cash & ST Investments$250M$203M$309M$240M$140M
Net Receivables$0$3M$38M$56M$159M
Inventory$0$10M$21M$27M$40M
Other Current Assets$4M$5M$8M$8M$17M
Total Current Assets$254M$220M$376M$332M$356M
Property, Plant & Equip.$32M$61M$58M$68M$74M
Goodwill & Intangibles$0$0$0$0$0
Long-Term Investments$0$0$0$0$0
Other Non-Current Assets$4M$4M$18M$2M$2M
Total Non-Current Assets$36M$65M$76M$70M$76M
Total Assets$290M$285M$453M$402M$431M
— Liabilities —
Accounts Payable$6M$12M$13M$9M$8M
Short-Term Debt$0$0$6M$5M$4M
Deferred Revenue$0$0$0$51M$64M
Other Current Liabilities$19M$38M$65M$40M$48M
Total Current Liabilities$25M$51M$84M$104M$125M
Long-Term Debt$124M$0$189M$210M$256M
Other Non-Current Liab.$6M$6M$13M$12M$3M
Total Non-Current Liabilities$129M$6M$202M$274M$324M
Total Liabilities$155M$57M$286M$378M$449M
— Equity —
Common Stock$37K$45K$46K$47K$48K
Retained Earnings-$462M-$696M-$896M-$1.1B-$1.2B
Accumulated OCI-$28K$0-$92K-$52K-$126K
Total Stockholders Equity$136M$228M$167M$24M-$17M
Total Liabilities & Equity$290M$285M$453M$402M$431M
— Key Metrics —
Total Debt$124M$0$194M$215M$261M
Net Debt-$74M-$203M$50M$64M$223M
Total Investments$52M$0$165M$89M$103M

Sign in to InsiderStreet

You'll also get our free weekly newsletter with
smart money signals, market insights, and alpha ideas.
Unsubscribe anytime.

For informational purposes only. Not investment advice. Data sourced from SEC filings. Privacy Terms